BIIB Q1 2024 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q1 2024 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$2.3B-7.0% YoY

Gross Profit

$1.8B78.3% margin

Operating Income

$690M30.1% margin

Net Income

$393M17.2% margin

EPS (Diluted)

$2.70

QoQ Revenue Growth

-4.0%

Cash Flow

Operating Cash Flow

$553M

Free Cash Flow

$432M

Stock-Based Comp.

$73M

Balance Sheet

Total Assets

$26.6B

Total Liabilities

$11.4B

Stockholders' Equity

$15.2B

Cash & Equivalents

$1.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.3B	$2.5B	-7.0%
Gross Profit	$1.8B	$1.8B	-0.4%
Operating Income	$690M	$574M	+20.2%
Net Income	$393M	$388M	+1.4%

Revenue Segments

MS Product Revenues

$1.1B43%

TYSABRI product

$431M17%

Fumarate

$382M15%

SPINRAZA

$341M14%

Interferon

$244M10%

Geographic Segments

Non-US

$966M56%

UNITED STATES

$746M44%